Free Newsletter
Scientists offer new drug target for stroke damage
A team of scientists drawn from the University of Central Florida and Louisiana State University has identified the mechanics at work during a stroke that causes cell death and spurs severe brain damage. And a new therapy that can interfere with that process could guard against the cell death that causes the damage.
Their insights revolve around an enzyme, DAPK-1, that binds to the NMDA receptor, which is usually working to prevent a fatal overload of calcium. The enzyme allows the calcium to flow in, killing cells and causing the damage.
"It is conceivable that this study not only provides new insights into the cellular and molecular basis responsible for stroke damage, but also provides a therapeutic target for stroke therapy," says Youming Lu, the LSU professor who led the team. And a colleague notes that the breakthrough could have significant implications for other areas of new drug development for neurodegenerative diseases.
- here's the story from UCF
Related Article:
Cheap antibiotic could offer breakthrough stroke therapy
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: